OCUMETICS TECHNOLOGY CORP Aktie

Calgary, Alberta – TheNewswire - June 4, 2025 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “ Offering ”) of up to 6,000,000 units of the Corporation (“ Units ”) at a price of $0.35 per Unit for gross proceeds of up to $2,100,000. There will be no minimum subscription level for the Offering.  Each Unit will consist of one common share in the share capital of the Corporation (“ Common Share ”) and one-half of one common share purchase warrant. Each whole warrant (“ Warrant ”) will entitle the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of 24 months from the date of issuance of the Warrant.   The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at ‎‎least $0.60 per Common Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be ‎accelerated by the Corporation to a date that is not less than 30 days after the date that ‎notice of such acceleration is provided to the Warrant holders by way of a press release.» Mehr auf thenewswire.com

Calgary, Alberta - TheNewswire - – June 3, 2025 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has set June 26, 2025 as the date for its first-in-human (FIH) clinical study.   The FIH clinical study involves the implantation of the Company's inaugural accommodating intraocular lens (the “Ocumetics Lens”) in the first group of study patients at a designated clinic in Mexico City.  This milestone marks a historic moment for Ocumetics - culminating nearly two decades of relentless innovation, research, and development.» Mehr auf thenewswire.com

Calgary, Alberta – TheNewswire - May 22, 2025 - Ocumetics Technology Corp . (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the submission of its first-in-human (FIH) clinical study protocol for IRB approval.  This development represents a critical step in the advancement of the Ocumetics Lens toward clinical trials planned for summer 2025, designed to assess safety, effectiveness, and performance of Ocumetics' innovative lens technology in human subjects for the first time. Dean Burns, CEO of Ocumetics, stated: “The development of our first-in-human study protocol is a major step forward and reflects our commitment to scientific rigor and patient safety.  With the protocol and study endpoints now in place, we are preparing for regulatory submission and study site initiation.  We are excited to move into the clinical phase of development with strong partners and a clear path forward.”» Mehr auf thenewswire.com